Company page

Immatics N.v.

Immatics N.V. is a public biotechnology company traded under the ticker IMTX in the American market. The company focuses on developing innovative T-cell receptor (TCR) therapies for cancer treatment. With a market capitalization of approximately $1.31 billion, Immatics is dedicated to advancing its proprietary technology to improve patient outcomes in oncology.